Giorgio Treglia1,2,3,4,5*- 1Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- 2Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland
- 3Academic Education, Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- 4Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
- 5Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global emergency caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified from an outbreak in Wuhan (China) in December 2019, then the infection rapidly spread across the globe. The World Health Organization (WHO) declared COVID-19 a pandemic on 11 March 2020. As of 28 December 2021, the pandemic had caused more than 280 million cases and 5.4 million deaths (1).
The COVID-19 pandemic had an impact in several medical fields, including nuclear medicine. Nuclear medicine procedures are used for functional imaging of pathophysiological processes at cellular or molecular levels using specific diagnostic radiopharmaceuticals and for treatment of several diseases based on targeted delivery of therapeutic radiopharmaceuticals. COVID-19 has created several challenges related to organizational, clinical/imaging, and research settings in nuclear medicine.
Regarding organizational aspects, based on several international surveys and initiatives, it is currently well-known that the COVID-19 pandemic had a significant impact on the activities of nuclear medicine departments worldwide (2–11). For instance, the volume of nuclear medicine diagnostic and therapeutic procedures declined globally (for several reasons including reduced activity of some centers, postponements of non-urgent procedures, and patients' fear about COVID-19) with variable degrees of restoration and possible impact on patient management (2). COVID-19-adapted nuclear medicine guidelines for standard operating procedures (SOPs) were created, including infection protection measures for patients and nuclear medicine staff (2). Furthermore, the COVID-19 pandemic also negatively influenced the supply of radiopharmaceuticals to nuclear medicine departments; on the other hand, applications of communications technologies in nuclear medicine increased including telemedicine and education (2).
Regarding clinical/imaging aspects, hybrid imaging techniques may provide functional and morphological information for early diagnosis of infectious and inflammatory diseases (12), including COVID-19. Evidence-based data demonstrated that several nuclear medicine procedures and hybrid imaging techniques may incidentally detect COVID-19 lesions (e.g., interstitial pneumonia suspected for COVID-19) in patients who underwent these imaging techniques for oncological and non-oncological indications (13, 14). Notably, hybrid imaging methods are currently not used in the clinical practice to diagnose COVID-19 or for disease monitoring and they cannot substitute high-resolution computed tomography in this setting (15). However, incidental early diagnosis of COVID-19 through hybrid imaging techniques may be crucial for appropriate patient management (13, 14).
As of 28 December 2021, about 9 billion doses of COVID-19 vaccines have been administered worldwide (1). Incidental findings using hybrid imaging methods in patients who have received COVID-19 vaccinations, including hypermetabolic axillary lymph nodes ipsilateral to the COVID-19 vaccine injection site, have been widely described (16, 17). These imaging findings are frequent and they may cause diagnostic dilemmas, in particular, in oncological patients. Nuclear medicine physicians must be aware and recognize the significant frequency of hybrid imaging findings related to immune response to vaccine injection (16, 17).
Overall, COVID-19 and COVID-19 vaccination may cause a strong activation of the immune system leading to incidental hybrid imaging findings as local inflammation (frequent finding) or triggered autoimmune diseases (unusual finding) (18).
Regarding the research setting, the COVID-19 pandemic incentivized research activities in several medical fields including nuclear medicine. Several researchers described the potential use of nuclear medicine techniques for evaluating patients with COVID-19 (19). Furthermore, nuclear medicine will likely become a more important part of future antiviral drug development and treatment (20). On the other hand, the COVID-19 pandemic had a negative impact on imaging, not only for patient care but also for clinical trials (21).
Despite the well-recognized impact of the COVID-19 pandemic in clinical and research activities in nuclear medicine, researchers have adopted the mantra of “the show must go on.” To maintain the continuity of essential nuclear medicine services is considered a priority at the international level (2). Nuclear medicine education has been adapted to the pandemic setting (2). Furthermore, it is important to underline that the research activities in nuclear medicine will not end due to the COVID pandemic. Conversely, research activities are significantly growing considering, among others, innovating technologies, novel radiopharmaceuticals, emerging indications, and new methods of imaging/data analyses which will guarantee a bright future for the discipline.
Author Contributions
The author confirms being the sole contributor of this work and has approved it for publication.
Conflict of Interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Available online at: https://covid19.who.int/ (accessed December 28, 2021).
2. Paez D, Mikhail-Lette M, Gnanasegaran G, Dondi M, Estrada-Lobato E, Bomanji J, et al. Nuclear medicine departments in the era of COVID-19. Semin Nucl Med. (2022) 52:41–7. doi: 10.1053/j.semnuclmed.2021.06.019
3. Moreira AP, Jamar F, Ozcan Z, Piciu D, Als C, Franceschi M, et al. Impact of the COVID-19 pandemic on nuclear medicine departments in Europe. Eur J Nucl Med Mol Imaging. (2021) 48:3361–4. doi: 10.1007/s00259-021-05484-z
4. Kirienko M, Telo S, Hustinx R, Bomanji JB, Chiti A, Fanti S. The impact of COVID-19 on nuclear medicine in Europe. Semin Nucl Med. (2022) 52:17–24. doi: 10.1053/j.semnuclmed.2021.06.022
5. Antonios L, Chen W, Dilsizian V. The impact of COVID-19 on nuclear medicine operations including cardiovascular manifestations in the USA. Semin Nucl Med. (2022) 52:11–6. doi: 10.1053/j.semnuclmed.2021.06.003
6. Bom HH, Pascual TN, Choudhury PS, Al-Ibraheem A. Impact of COVID-19 on nuclear medicine in Asia. Semin Nucl Med. (2022) 52:25–30. doi: 10.1053/j.semnuclmed.2021.06.001
7. Currie G. COVID19 impact on nuclear medicine: an Australian perspective. Eur J Nucl Med Mol Imaging. (2020) 47:1623–7. doi: 10.1007/s00259-020-04812-z
8. Giammarile F, Delgado Bolton RC, El-Haj N, Mikhail M, Morozova O, Orellana P, et al. Impact of COVID-19 on nuclear medicine departments in Africa and Latin America. Semin Nucl Med. (2022) 52:31–40. doi: 10.1053/j.semnuclmed.2021.06.018
9. Giammarile F, Delgado Bolton RC, El-Haj N, Freudenberg LS, Herrmann K, Mikhail M, et al. Changes in the global impact of COVID-19 on nuclear medicine departments during 2020: an international follow-up survey. Eur J Nucl Med Mol Imaging. (2021) 48:4318–30. doi: 10.1007/s00259-021-05444-7
10. Freudenberg LS, Paez D, Giammarile F, Cerci J, Modiselle M, Pascual TNB, et al. Global impact of COVID-19 on nuclear medicine departments: an international survey in April 2020. J Nucl Med. (2020) 61:1278–83. doi: 10.2967/jnumed.120.249821
11. Annunziata S, Bauckneht M, Albano D, Argiroffi G, Calabrò D, Abenavoli E, et al. Impact of the COVID-19 pandemic in nuclear medicine departments: preliminary report of the first international survey. Eur J Nucl Med Mol Imaging. (2020) 47:2090–9. doi: 10.1007/s00259-020-04874-z
12. Treglia G. Diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases according to published meta-analyses. Contrast Media Mol Imaging. (2019) 2019:3018349. doi: 10.1155/2019/3018349
13. Annunziata S, Delgado Bolton RC, Kamani CH, Prior JO, Albano D, Bertagna F, et al. Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: a systematic review. Pharmaceuticals. (2020) 13:377. doi: 10.3390/ph13110377
14. Rafiee F, Keshavarz P, Katal S, Assadi M, Nejati SF, Ebrahimian Sadabad F, et al. Coronavirus disease 2019 (COVID-19) in molecular imaging: a systematic review of incidental detection of SARS-CoV-2 pneumonia on PET studies. Semin Nucl Med. (2021) 51:178–91. doi: 10.1053/j.semnuclmed.2020.10.002
15. Treglia G. The role of 18F-FDG PET for COVID-19 infection: myth versus reality. Clin Transl Imaging. (2020) 8:125–6. doi: 10.1007/s40336-020-00367-z
16. Treglia G, Cuzzocrea M, Giovanella L, Elzi L, Muoio B. Prevalence and significance of hypermetabolic lymph nodes detected by 2-[18F]FDG PET/CT after COVID-19 vaccination: a systematic review and a meta-analysis. Pharmaceuticals. (2021) 14:762. doi: 10.3390/ph14080762
17. Treglia G, Cuzzocrea M, Muoio B, Elzi L. PET findings after COVID-19 vaccination: “Keep Calm and Carry On”. Clin Transl Imaging. (2021) 9:209–14. doi: 10.1007/s40336-021-00430-3
18. Sollini M, Gelardi F, Biroli M, Chiti A. Patients' findings after COVID-19 infection and vaccinations: what to expect from [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. (2021) 49:791–5. doi: 10.1007/s00259-021-05652-1
19. Juengling FD, Maldonado A, Wuest F, Schindler TH. Identify. Quantify. Predict. Why immunologists should widely use molecular imaging for coronavirus disease 2019. Front Immunol. (2021) 12:568959. doi: 10.3389/fimmu.2021.568959
20. Neumaier F, Zlatopolskiy BD, Neumaier B. Nuclear medicine in times of COVID-19: how radiopharmaceuticals could help to fight the current and future pandemics. Pharmaceutics. (2020) 12:1247. doi: 10.3390/pharmaceutics12121247
Keywords: nuclear medicine (NM), COVID-19, hybrid imaging, imaging, research
Citation: Treglia G (2022) Nuclear Medicine During the COVID-19 Pandemic: The Show Must Go On. Front. Med. 9:896069. doi: 10.3389/fmed.2022.896069
Received: 14 March 2022; Accepted: 30 March 2022;
Published: 12 May 2022.
Edited and reviewed by: Michel Goldman, Institute for Interdisciplinary Innovation in Healthcare (I3h), Belgium
Copyright © 2022 Treglia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Giorgio Treglia, giorgio.treglia@eoc.ch